chrisvoncsefalvay/vaers-outcomes huggingface dataset:
feeling sick; blood sugar is low; cancelled his appointment for the second dose in the series; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (feeling sick), BLOOD GLUCOSE DECREASED (blood sugar is low) and PRODUCT DOSE OMISSION ISSUE (cancelled his appointment for the second dose in the series) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (cancelled his appointment for the second dose in the series). On an unknown date, the patient experienced MALAISE (feeling sick) and BLOOD GLUCOSE DECREASED (blood sugar is low). At the time of the report, MALAISE (feeling sick), BLOOD GLUCOSE DECREASED (blood sugar is low) and PRODUCT DOSE OMISSION ISSUE (cancelled his appointment for the second dose in the series) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medication information was reported.
Information has been received from a physician and the office manager concerning a 61 day old female patient who on 27-MAR-2009, was vaccinated with PNEUMOVAX (lot # 661934/1441X) instead of PREVNAR by mistake due to an office error. It is unknown if the patient sought medical attention. Follow up information was received from the physician which reported that the patient was vaccinated IM with PNEUMOVAX (lot # 661934/1441X). There was no illness at the time of vaccination. No reactions or adverse events were reported. The patient did not seek medical attention. This is one of several reports from the same source. Additional information is not expected.
Tongue swelling; This spontaneous case was reported by a pharmacist and describes the occurrence of SWOLLEN TONGUE (Tongue swelling) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023m20a) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, the patient experienced SWOLLEN TONGUE (Tongue swelling). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) for Tongue swelling non-specific, at a dose of 25 mg four times per day. At the time of the report, SWOLLEN TONGUE (Tongue swelling) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.
Round painful itchy rash about the size of a silver dollar, possibly larger. Red inflamed swollen like a large fist. Hot, itchy, very painful, incredibly itchy. It's been 98 hours now and the swelling it down some, but the rash, swelling, pain, itching are all present, just to a lesser degree. The main pain and swelling were from 12 hours after until 86 hours after.
pain right side of chest; neck pain; headache; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CHEST PAIN (pain right side of chest), NECK PAIN (neck pain) and HEADACHE (headache) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013720A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced NECK PAIN (neck pain) and HEADACHE (headache). On 25-Feb-2021, the patient experienced CHEST PAIN (pain right side of chest). On 22-Feb-2021, NECK PAIN (neck pain) and HEADACHE (headache) had resolved. At the time of the report, CHEST PAIN (pain right side of chest) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   Concomitant medications were not provided.  Treatment information was not provided by reporter.   Action taken with the drug in response to the events was not applicable.
injection which she states is way over due; missed dose; Inability to afford medication; This spontaneous report was received from a female patient of unknown age, reporting on herself. Information regarding the patient's pertinent medical history, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not provided.  On an unknown date, the patient was vaccinated with a first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (formulation, exact dose, route of administration, vaccination scheme frequency, anatomical location, lot number and expiration date were not reported).  At the reporting time, the patient was seeking assistance for her second hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) injection which she stated was over due because she can not afford it (inappropriate schedule of product administration, inability to afford medication and product dose omission issue).
arm is a little sore; Initial information received on 01-Dec-2020 regarding an unsolicited valid non-serious case from a consumer (patient).   This case involves a patient of unknown demographics who reported his/her arm was a little sore (pain in extremity), while the patient received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medication was not reported.  On 30-Nov-2020, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiration date) not reported via unknown route in unknown administration site for prophylaxis vaccination.  On 30-Nov-2020, same day after administration of the suspect vaccine therapy, patient's arm was a little sore (pain in extremity) but felt good and was looking forward to a healthy winter.   No laboratory data was provided.   It was not reported if the patient received a corrective treatment.  At the time of report, the outcome was unknown for the event.     There will be no information available on the batch number for this case.
This spontaneous report as received from a registered nurse refers to a unspecified group of children of unknown age and gender. At an unknown date, the patients were vaccinated with VARIVAX (Merck) injection. Route, dose and frequency were not reported. No other co-suspects were reported. No concomitant medications were reported. Nurse reported that in the past she has heard about an unspecified number of cases where children received VARIVAX and developed generalized varicella-like lesions. These were not her patients and she had no other information. No other details. Additional information has been requested.
red, bruised area on lt thigh @ site of inj; tender to touch, fussy 4 days, fever 100 x 2 days; restless, unable to sleep well; APAP given q 4 hrs for 4 days; 23AUG95 2cm area of induration lt- no redness, no swelling, + tenderness
This spontaneous report was received from a registered nurse and refers to a 12 months old patient of unknown gender. No medical history, concurrent conditions and concomitant therapies were reported. On 01-JUN-2015, the patient was vaccinated with improperly stored dose of (Oka/Merck) VARIVAX lot # K021933, expiration date 10-NOV-2016, dose 0.5 ml, subcutaneously (anatomical location was not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected.
COVID 19; COVID 19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old male patient received BNT162b2 (BNT162B2), on 31Mar2022 as dose 4 (booster), single (Lot number: Fm7753) at the age of 67 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. It was reported that the patient had No Known allergies.   The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown Results, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19. It was reported that the patient received treatment of Plaxovid on 08Jl2022.
Fever 102.3 rectally and increased fussiness that started in evening of 6/26/06. Patient was seen in office 6/27/06 and evaluated by doctor and patient's mom instructed to give Tylenol Q 4 for 24 hours, keep hydrated and follow up as necessary.
Notified by client that she received the H1N1 injection on 4/15/2010, and required hospitalization for 3 days from allergic reaction. Client started 4/16/2010 at 2 AM woke up perspiring, stated she felt very tired. Chills and temperature of 101, malaise, started before 12PM that day. Client went to doctors office and was admitted. During hospitalization she started having abdominal cramping and diarrhea. Private physician said she was probably having an allergic reaction to H1N1 vaccine. Discharged on 04/18/2010. States no problems at this time. Treatment - I.V. fluids. Medicine - abdominal cramping.
This case was reported by a consumer via call center representative and described the occurrence of shingles in a 72-year-old female patient who received SHINGRIX for prophylaxis. On 4th September 2018, the patient received the 1st dose of SHINGRIX. On 17th September 2018, 13 days after receiving SHINGRIX, the patient experienced shingles and pruritus. On an unknown date, the outcome of the shingles and pruritus were not recovered/not resolved. The reporter considered the shingles and pruritus to be related to SHINGRIX. Additional details were reported as follows: On 17th or 18th September 2018, she developed what she thought was a mosquito bite that was very itchy. The mosquito bite multiplied and she went to her doctor the day of reporting and was diagnosed with shingles.
Bell's Palsy developed more than two weeks after the first dose. The patient had postponed his second dose due having what his wife described as a severe GI flu. On the day he was originally scheduled to come in for his second dose he developed drooping on one side of his face and his wife took him to the ER suspecting a stroke. Testing ruled this out and he was diagnosed with Bell's Palsy. He was treated with valacyclovir and prednisone.
Hospitalization for Sepsis secondary to UTI and COVID-19 pneumonia on dates 8/15/2023- 8/19/2023. Treated with dexamethasone, baricitinib, and Remdesivir.
Hivess on left face. Small area of erythema/irritation of right Upper eyelid near brow, TX Benadryl 25mg cap OTC 1-2 po q4-6 hours PRN. HCTC 1% cream top 1 OTC  TID UD. ordered by Dr.
Post vax, the patient complained of paresthesia to the scotal area. Patient feels funny.
2 days after receiving vaccine, patient has been experiencing itchiness and swelling in bilateral eyes, and red, blotchy, pruritic areas to neck. Patient has been taking Benadryl with no effect. Also has been applying ice packs to neck area which has helped with some effect. Recommended an alternative antihistamine such as Zyrtec or Claritin. Patient has been prescribed prednisone from doctor but has not taken prednisone yet. Will try OTC medications first per caller. Recommended to see provider if symptoms worsen.
hardness at injection site; Large red spot 3 and a half inches; injection site tender; Can't raise hand; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (Can't raise hand), VACCINATION SITE INDURATION (hardness at injection site), VACCINATION SITE ERYTHEMA (Large red spot 3 and a half inches) and VACCINATION SITE PAIN (injection site tender) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history).    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jan-2021, the patient experienced VACCINATION SITE MOVEMENT IMPAIRMENT (Can't raise hand). On 15-Jan-2021, the patient experienced VACCINATION SITE INDURATION (hardness at injection site), VACCINATION SITE ERYTHEMA (Large red spot 3 and a half inches) and VACCINATION SITE PAIN (injection site tender). At the time of the report, VACCINATION SITE MOVEMENT IMPAIRMENT (Can't raise hand), VACCINATION SITE INDURATION (hardness at injection site), VACCINATION SITE ERYTHEMA (Large red spot 3 and a half inches) and VACCINATION SITE PAIN (injection site tender) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jan-2021, Pain assessment (0-10): 6.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication details were not reported by the reporter. Treatment included Benadryl.
HAD VACCINES ON 5/22/07 DEVELOPED SWELLING, REDNESS AND PAIN IN THE LEFT DELTOID AREA.  WAS SEEN IN THE OFFICE ON 5/29/07 MUCH IMPROVED ALLEGEDLY LASTED 5-6 DAYS.  FINDINGS ON 5/29/07 WERE A BRUISE ON THE LEFT UPPER ARM APPROXIMATELY 2-3 CM, ASSOCIATED ERYTHEMA APPROXIMATELY 8-10 CM. NO PAIN, SWELLING, OR TENDERNESS.
This spontaneous report was received from a health professional (medical assistant) refers to unspecified patients of unknown age and gender. The patient's medical history and concurrent conditions were not reported. Concomitant medications included sterile diluent. On an unknown date, in 2017 (reported as "20-JUL-2017 to 18-AUG-2017") improperly stored doses of PROQUAD (lot # N004629, expiration date # 07-AUG-2017) (route, dose number, dose, frequency) were administered to unspecified patients for prophylaxis. No adverse effects were reported. The vaccines were exposed to a temperature 15 degrees F to 46 degrees F for a time period of 3 hours. There was no previous temperature excursions. Digital data logger was not involved. No additional information was provided. Product quality complaint (PQC) was not reported.
Onset 12/21 of itching, redness, swelling to RA at vacc inj site; size approx 2" diam; instructed to apply warm compresses & take BENADRYL 25mg q6 hours prn.
About 18 hours after the vaccination, I noticed itching on the back of the head, then welts, then  terrible buttocks itching and welts. 20 hours later one droopy eye. 32 hours later swollen shut eyes , lips and checks swollen. Back and buttocks were red and extremely itchy! Was treated with Anthistamine at Emergency Room. 4 days later I was recovered with steroids!
Experienced some fatigue after vaccine, as possible side effect. Over next couple of months I noticed I was fatigued more than I normally had been, maybe a couple times a month.  It was worse in April as it would come on quickly and require I lie down and rest or nap. I have never been a person to take naps.  Scheduled exercise class got to be more effort. It continues a couple times a month.  I also had BP dropping low, systolic in 80's and 90's, diastolic in 60's.  Heart rate is often in 50's or 60's.  I get dizzy if I bend and stand up,  and still experience low energy.   I am working with my cardiologist, stress test was good, kidney blood flow ultrasound also good.  Cardiac CT is scheduled.  I don't know if this is vaccine related,  just that it started within a couple months after vaccine and experiencing some fatigue after vaccine.   I also had an ER visit for colitis, which was a first.  No reason identified.
Patient stated she is considered legally blinded; This spontaneous case was reported by a consumer and describes the occurrence of VISUAL IMPAIRMENT (Patient stated she is considered legally blinded) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In August 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In August 2021, the patient experienced VISUAL IMPAIRMENT (Patient stated she is considered legally blinded). At the time of the report, VISUAL IMPAIRMENT (Patient stated she is considered legally blinded) outcome was unknown.            No concomitant medication was provided. No treatment medication were provided. It was reported that patient had no allergic history. Patient had never test or diagnosis of COVID. No other vaccines was received by the patient within 1 month prior to Moderna COVID-19 vaccine.  It was reported that patient visited different doctors after this symptom began and patient made a lot of medical tests but patient did not had any autoimmune diseases. Some doctors told patient that it may be caused by meningitis, or due to COVID-19. Patient was afraid that her health will get worse.   Reporter did not allow further contact
Within 30 seconds of receiving Varivax, client felt itchy at injection site. Within 1-2 minutes, felt lightheaded, flushed, itchy, tingling in fingers, dizzy and slight tightness in chest. Left upper arm warm and red at injection site. Vital signs monitored, ice pack to left arm injection site. Taken to hospital via ambulance.
Itchy at the injection site; Red at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (Itchy at the injection site) and INJECTION SITE ERYTHEMA (Red at the injection site) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE PRURITUS (Itchy at the injection site) and INJECTION SITE ERYTHEMA (Red at the injection site). On 19-Mar-2021, INJECTION SITE PRURITUS (Itchy at the injection site) and INJECTION SITE ERYTHEMA (Red at the injection site) had resolved.            No Concomitant medications were reported.  No treatment medications were reported.  Patient took the second dose on 15-MAR-2021 (lot no. 002D21A)   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up information received on 16 Jul 2021 contains updated contact information, updated date of first dose, second dose information and updated outcome of all the events as recovered with stop date.
Information has been received from a healthcare professional, concerning a 5 year old female patient who on 09-OCT-2007 was vaccinated with a dose of PNEUMOVAX 23 (lot #658075/0962U).  On the day of vaccination, the patient developed cellulitis.  At the time of this report, the outcome of the event was unknown.  Additional information has been requested.
Between 5 to 10 minutes following the immunization, the patient and her mother returned to the pharmacy with complaints of not feeling well. She was pale, and complained of her ears popping, her eye hurting, and being very thirsty. She was instructed to sit and then to lie down while I assessed her. She had no immediate sings of an allergic reaction including no signs of labored/difficulty breathing, no signs of a rash or hives, no difficulty swallowing. Her pulse was normal and her blood pressure was normal. At her mothers request, 911 was called. Upon their arrival, they performed an initial assessment in the store and then transported her to the ambulance for further assessment. After a short time the patient was released and returned home.   After the patient was released, her mother returned to the pharmacy to let us know that she was okay and was feeling much better. Additionally, she recalled that patient had had a similar but less severe response to the flu shot last year. Sh had complained of her ears popping and generally not feeling well.
This spontaneous report was received from a health professional refers to a patient of an unknown age. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 28-AUG-2017 four months of age, inadvertently received PNEUMOVAX 23 (0.5ml/once, intramuscular with a lot number M043424 and expiry date 06-JUN-2018 instead of PREVNAR 13. No adverse effects were reported.
The day after the vaccines, the patient experienced fever and severe body aches (including stiffness in the neck) and headache for 4 days. Patient called her PCP, who said he thought it was due to the vaccines. After 4 days symptoms began to resolve. The only lingering symptoms were slight redness and itchiness at vaccination sites (both arms), but she was feeling much better.
Information has been received from a female pharmacist who on 16 Jan 2007 was vaccinated a dose with Zostavax.  On 17 Jan 2007 the patient experienced slight soreness in her upper arm and bruising around the injection site. She did not seek medical attention. Subsequently she recovered. There was no product quality complaint involved. No further information is available.
Slight fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Slight fever) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Slight fever). At the time of the report, PYREXIA (Slight fever) outcome was unknown. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided. No concomitant medications were reported.